SkinJect Clinical Trial Receives FDA "Study May Proceed" Letter

Medicus Pharma recently announced that the U.S. Food and Drug Administration (FDA) has issued a Study May Proceed letter for its planned SkinJect clinical trial in people with Gorlin syndrome.

A Study May Proceed letter means the FDA has reviewed the information submitted by the company and has not identified any issues that would prevent the clinical study from moving forward. It does not mean the treatment has been approved or that the study has begun enrolling participants.

According to Medicus Pharma, the upcoming study is intended to evaluate SkinJect, an investigational treatment for basal cell carcinomas (BCCs) in people with Gorlin syndrome. The company has indicated that this will be a registrational study, meaning the results may be used to support a future application for FDA approval if the treatment is shown to be safe and effective.

At this time, Medicus Pharma has not announced when enrollment will begin or which clinical sites will participate. Additional information is expected as the study moves forward.

The Gorlin Syndrome Alliance will continue to monitor developments and share updates as information becomes available. As always, participation in any clinical trial is a personal decision that should be discussed with your healthcare team.

Source: Medicus Pharma press release. Read the original announcement here.